ROCHESTER, NY (March 7, 2023) Renowned neuroscientist Dr. James E. Galvin has joined Cognivue as Chief Scientific Officer. He is the founding director of the Comprehensive Center for Brain Health, professor of Neurology, and professor of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine.

Dr. Galvin will remain at the University of Miami while assuming his new role at Cognivue, where he has served on the company’s clinical advisory board since March 2022.

“Dr. Galvin brings Cognivue a wealth of knowledge and powerful experience to help advance the gold standard of cognitive health assessment.  As we work to empower action on early detection, Jim’s interest in reaching diverse populations through his research is especially noteworthy. It has brought greater awareness and adoption of cognitive health assessments among underserved communities,” said Cognivue President and CEO Tom O’Neill. “For Cognivue technology to truly make a difference, it must represent the broad clinical spectrum of a growing at-risk population. Jim’s expertise makes him uniquely equipped for this role.”

As Chief Scientific Officer, Dr. Galvin is responsible for developing and executing a scientific plan that includes study and protocol development and execution, study sponsorship, abstract development, and publications that establish best clinical outcomes for Cognivue cognitive health assessment products across all strategic specialties and channels.

Dr. Galvin said, “I am excited to take on the role of Chief Scientific Officer to help develop and expand the full research capabilities and potential of Cognivue. I look forward to working with Cognivue team and interacting with members of our clinical advisory board and Key Opinion Leaders in academia and clinical practice”

A board-certified neurologist, Dr. Galvin has published more than 330 peer-reviewed papers in top-tier scientific journals and received over $100 Million in research funding from the National Institutes of Health. Of particular interest to Dr. Galvin and his team is the impact of sex, race, ethnicity, socioeconomic status, and geographic locale on brain health and the risk of future cognitive and functional impairment.

Dr. Galvin’s research focus is on the development of novel and innovative approaches to study brain health and the risk of cognitive impairment, holding 22 copyrights for instruments used across the world including the AD8, Quick Dementia Rating System (QDRS), and Lewy Body Composite Risk Score (LBCRS). At the University of Miami, he leads a multidisciplinary team of physicians, scientists, and researchers to investigate clinical, cognitive, functional, and behavioral features of healthy brain aging and neurodegenerative disease and their relationship to novel biomarkers of brain pathology including structural, functional and diffusion MRI, amyloid and tau PET scans, blood biomarkers of Alzheimer’s and Parkinson’s disease, electrophysiology, and computer-based behavioral testing.

About Cognivue, Inc.

Cognivue, Inc. is a world-class neuroscience company focusing on cognitive health with the world’s first FDA-cleared computerized test of cognitive function. The Cognivue device and technology are based on years of research that uses adaptive psychophysics to focus on information processing by testing key cognitive domains. The technology significantly improves the ability of healthcare providers to implement a personalized assessment of cognitive function in a wide variety of care settings. The company is elevating the gold standard of cognitive health assessment and empowering the healthcare community to monitor, identify and act early on cognitive health concerns.

For more information, call (585) 203-1969 or visit cognivue.com.

Media Contact:

Dan Smith

McDougall Communications for Cognivue, Inc.

dan@mcdougallpr.com

(585) 434-2154